Weight-Loss Drugs Have Opened the Door, and Obesity Care Is Moving Toward an Era of Combination Therapy

Obesity care has undergone a rare shift in tone in recent years: what was once often reduced to a matter of willpower, diet, or exercise is now more clearly being placed back within the framework of chronic disease and metabolic biology. GLP-1-related drugs such as Ozempic, Wegovy, Mounjaro, and Zepbound have allowed many patients to see weight-loss effects that were previously difficult to achieve, and have also prompted physicians to rethink the idea that obesity treatment should have only one path.

Experts affiliated with the American Gastroenterological Association published a commentary in *Gastroenterology* reexamining the POWER practice guide on obesity and weight management proposed in 2017. The core message of this update is not that drugs have solved obesity, but that the GLP-1 era has expanded treatment options, making it more necessary in clinical practice to place medications, endoscopic weight-loss therapies, bariatric surgery, and personalized assessment on the same map.

GLP-1 receptor agonists were originally used for diabetes and metabolic control, and later expanded rapidly in weight-loss treatment because they can affect appetite, gastric emptying, and energy intake. The emergence of these drugs has indeed changed medical practice, but the commentary authors emphasize that obesity involves multiple factors, including the liver, gastrointestinal tract, cardiovascular system, endocrine system, and behavioral environment. Relying solely on weight numbers or body mass index is often insufficient to determine a person’s health risks and treatment needs.

As a result, the new discussion incorporates the concept of “clinical obesity”: the focus is not only whether BMI exceeds a threshold, but whether excess fat has already impaired organ function, metabolic status, or quality of life. This perspective can shift treatment away from simply pursuing weight reduction and toward more nuanced questions: which patients are suited to starting with medication, which may need endoscopic intervention, which situations should prompt early surgical evaluation, and how the effects should be maintained after treatment.

Endoscopic obesity and metabolic therapies are another growing area mentioned in the commentary. Procedures such as endoscopic sleeve gastroplasty, for example, seek to provide a less invasive option between medications and traditional surgery. Existing evidence is accumulating on their effectiveness, but different techniques, patient characteristics, and follow-up durations still affect outcomes, so they cannot simply be viewed as substitutes for drugs.

The more forward-looking vision is combination therapy and precision medicine. The commentary notes that GLP-1 drugs, when paired with endoscopic procedures or bariatric surgery, may bring greater weight loss and more durable effects; genomics and other biomarkers may also help determine who is likely to respond better to which treatment. However, this remains a developing clinical direction, and clearer long-term data are still needed to answer questions about durability of efficacy, side effects, rebound after drug discontinuation, cost, and accessibility.

Gastroenterologists and hepatologists are being given a more important role in this transition, for a straightforward reason: they frequently care for metabolic dysfunction-associated fatty liver disease, gastroesophageal reflux, gallbladder disease, and other gastrointestinal complications related to obesity. As obesity treatment moves from a single prescription toward multispecialty collaboration, the clinical challenge is also shifting from “whether to lose weight” to “how to arrange a treatment pathway for different patients that is affordable, sustainable, and proportionate to risk.”